IPHYF OTC
Innate Pharma S.A.
1W: -8.5%
1M: -8.5%
3M: -8.5%
YTD: -29.8%
1Y: -24.5%
3Y: -44.3%
5Y: -65.8%
$1.51
-0.14 (-8.53%)
Weekly Expected Move ±4.2%
$1
$1
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$3M
-77.9% ▼
5Y CAGR: -47.5%
Gross Profit
$0
-100.0% ▼
Operating Income
-$60M
-16.7% ▼
Net Income
-$49M
+0.6% ▲
EPS (Diluted)
$-0.55
+9.8% ▲
EBITDA
-$59M
-25.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $12M | $50M | $62M | $13M | $3M |
| YoY Growth | -82.6% | +309.8% | +24.2% | -79.5% | -77.9% |
| Cost of Revenue | $47M | $52M | $56M | $0 | $0 |
| Gross Profit | -$22M | $6M | $6M | $13M | $0 |
| Gross Margin | -184.1% | 12.1% | 9.1% | 100.0% | 0.0% |
| R&D Expenses | $47M | $52M | $56M | $52M | $44M |
| SG&A Expenses | $26M | $14M | $18M | $12M | $18M |
| Operating Expenses | $26M | $63M | $18M | $64M | $62M |
| Operating Income | -$48M | -$57M | -$13M | -$52M | -$60M |
| Operating Margin | -394.9% | -115.7% | -20.6% | -408.6% | -2161.0% |
| Interest Expense | $312K | $288K | $640K | $566K | $3M |
| Income Before Tax | -$45M | -$58M | -$8M | -$49M | -$55M |
| Tax Expense | $0 | $0 | $0 | $0 | -$6M |
| Net Income | -$53M | -$58M | -$8M | -$49M | -$49M |
| Net Margin | -436.0% | -117.1% | -12.3% | -392.0% | -1764.5% |
| EPS (Diluted) | $-0.57 | $-0.73 | $-0.09 | $-0.61 | $-0.55 |
| EBITDA | -$43M | -$12M | -$8M | -$47M | -$59M |
| Shares Outstanding | 80M | 80M | 84M | 81M | 89M |